| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2655 | 2017 |
| Nivolumab plus ipilimumab in advanced non–small-cell lung cancer MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ... New England Journal of Medicine 381 (21), 2020-2031, 2019 | 2587 | 2019 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1474 | 2014 |
| Programmed death ligand-1 expression in non-small cell lung cancer V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ... Laboratory investigation 94 (1), 107-116, 2014 | 944 | 2014 |
| International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, P Debourdeau, M Beckers, C Baglin, RM Bauersachs, B Brenner, ... Journal of Thrombosis and Haemostasis 11 (1), 56-70, 2013 | 708 | 2013 |
| Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action A Kollias, KG Kyriakoulis, E Dimakakos, G Poulakou, GS Stergiou, ... British journal of haematology 189 (5), 846-847, 2020 | 643 | 2020 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 598 | 2019 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 588 | 2014 |
| FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal … J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, ... British journal of cancer 94 (6), 798-805, 2006 | 537 | 2006 |
| Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer V Michalaki, K Syrigos, P Charles, J Waxman British journal of cancer 90 (12), 2312-2316, 2004 | 532 | 2004 |
| Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ... The lancet oncology 16 (8), 897-907, 2015 | 519 | 2015 |
| Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 … SG Deftereos, G Giannopoulos, DA Vrachatis, GD Siasos, SG Giotaki, ... JAMA network open 3 (6), e2013136-e2013136, 2020 | 474 | 2020 |
| Cell adhesion molecules: role and clinical significance in cancer N Makrilia, A Kollias, L Manolopoulos, K Syrigos Cancer investigation 27 (10), 1023-1037, 2009 | 470 | 2009 |
| Objective measurement and clinical significance of TILs in non–small cell lung cancer KA Schalper, J Brown, D Carvajal-Hausdorf, J McLaughlin, V Velcheti, ... Journal of the National Cancer Institute 107 (3), dju435, 2015 | 435 | 2015 |
| 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer WEE Eberhardt, D De Ruysscher, W Weder, C Le Pechoux, P De Leyn, ... Annals of Oncology 26 (8), 1573-1588, 2015 | 426 | 2015 |
| International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer P Debourdeau, D Farge, M Beckers, C Baglin, RM Bauersachs, B Brenner, ... Journal of Thrombosis and Haemostasis 11 (1), 71-80, 2013 | 393 | 2013 |
| Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ... Annals of Oncology 25 (9), 1681-1690, 2014 | 378 | 2014 |
| Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non–small cell lung cancer using spatially resolved and multiparametric single-cell analysis I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ... Clinical Cancer Research 25 (15), 4663-4673, 2019 | 302 | 2019 |
| 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson, L Paz-Ares, M Reck, ... Annals of Oncology 25 (8), 1475-1484, 2014 | 291 | 2014 |
| Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery D Alexiou, AJ Karayiannakis, KN Syrigos, A Zbar, A Kremmyda, I Bramis, ... European Journal of Cancer 37 (18), 2392-2397, 2001 | 281 | 2001 |